In a near future we will be able to detect a concussion by taking a simple blood sample. Several research studies have already confirmed the results and the potential has gained substantial international attention. Behind this new diagnostics technique we find the Umeå based Swedish company, UmanDiagnostics, in collaboration with American Quanterix.
Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.
Umeå company Betagenon receives €1.8 million, from EU's sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and associated cardiovascular disease. The AMPK activator O304 is the first AMPK activator to reach clinical phase II trials
Asarina Pharma, a drug development company focused on the development of a novel therapy for severe premenstrual symptoms, has completed a financing round raising EURO 7 million from new and existing investors for the continued clinical development of Sepranolone.
Umecrine Cognition AB has announced the closing of a financing round raising SEK 45 million (US$4.9 million) in accordance with the company’s strategy to develop and commercialize its lead compound GR3027 for the treatment of patients with liver cirrhosis and hepatic encephalopathy.
The unique fibrosis model offered by InfiCure is attracting international attention. Last month the startup signed their first contract for a full-service preclinical pilot study to test two substances for an american client in Boston. The trial i currently underway, with all lab work beeing done on location in Umeå.
Clinical trials, intellectual property, and the entrepreneurship in medicine were just a few topics at the panel debate 24 of November. This year’s edition of the national roadshow Bubbel & Debatt took place at Umeå University where around 30 guests joined the panel in discussions on possibilities and hurdlers for innovation and collaboration in the life science field.
Umecrine Cognition announces positive top-line Phase 1 data with GR3027 in hepatic encephalopathy demonstrating safety, tolerability and CNS target engagement
Big pharma companies have tried and failed. But a small start-up in Umeå may have cracked the code. Betagenon has recently initiated a phase II clinical trial aiming to prove that obesity, diabetes and cardiovascular disease can all be treated by the same drug in humans.
The number of women in leading positions Umeå Biotech Incubator’s startup companies has tripled. Interesting and promising in itself, but also with the perspective that Vinnova are looking for more women innovation talents.
Successful projects with high potential for patient benefit gives Umeå Biotech Incubator renewed confidence from the Erling-Persson Family Foundation.
Biotech Umeå Investment Day 2017
Early drug development - 2 day interactive course
Regulatory for medical devices - Regelverk för medicinteknik
Biotech Umeå, Uminova Innovation
Box 7978, SE-907 19 Umeå